Loading clinical trials...
Loading clinical trials...
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Conditions
Interventions
efatutazone
Locations
127
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
University of Colorado Hospital
Aurora, Colorado, United States
Yale University
New Haven, Connecticut, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
Northside Hospital
Atlanta, Georgia, United States
Start Date
February 11, 2015
Primary Completion Date
October 4, 2018
Completion Date
May 1, 2023
Last Updated
January 27, 2025
NCT06422806
NCT06541262
NCT07432932
NCT07148050
NCT07377747
NCT06389799
Lead Sponsor
Alliance for Clinical Trials in Oncology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions